-
Product Insights
B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) - Drugs In Development, 2023’, provides an overview of the B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gepotidacin Mesylate in Cystitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gepotidacin Mesylate in Cystitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gepotidacin Mesylate in Cystitis Drug Details: Gepotidacin mesylate (GSK-2140944) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KN-026 in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KN-026 in Gastroesophageal (GE) Junction Carcinomas Drug Details: KN-026 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pelareorep in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pelareorep in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pelareorep in Refractory Multiple Myeloma Drug Details: Pelareorep (Reolysin) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EDP-323 in Respiratory Syncytial Virus (RSV) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EDP-323 in Respiratory Syncytial Virus (RSV) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EDP-323 in Respiratory Syncytial Virus (RSV) Infections Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GFH-009 in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GFH-009 in Diffuse Large B-Cell Lymphoma Drug Details: GFH-009 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy to Target CD19 for Leukemia and Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Gene Therapy to Target CD19 for Leukemia and Lymphoma Drug Details Gene therapy is...
-
Product Insights
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Acute lymphocytic leukemia (ALL) is a cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections, and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain, and breathing problems. Treatment includes chemotherapy, transfusions, transplant, and medications. The ALL pipeline drugs market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms may include night sweats, fever and chills that come and go, itching, putting pressure on the windpipe (trachea) or other airways, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if cancer affects the brain. Treatment includes surgery,...